Quality & Compliance

6 Tips for Evaluating Your CMO’s PAI Readiness

The submission of your drug application (NDA, ANDA, BLA, etc.) is an exciting accomplishment, and one of the first major milestones is a pre-approval inspection (PAI) of the manufacturing sites...

Regulatory Sciences

How Opioid Analgesic Drugs are Approved by the FDA

The benefit-risk assessment is the cornerstone of how all drugs are approved. This assessment captures the scientific evidence, uncertainties, policy, and reasoning used by FDA officials to arrive at...

Quality & Compliance

Conducting a PAI Mock Inspection: How to Execute and Evaluate Your Findings

Did you miss our last blog on PAI Readiness? Catch up here to learn what a PAI is and how to prepare. Congratulations! You conducted a Mock Inspection in preparation for your upcoming Pre-Approval...

3 Factors to Consider in the Manufacturing Phase for Drug Device Combination Products

Combination products represent an important and growing category of therapeutic and diagnostic products. They come in several configurations and can be composed of any combination of a drug and a...

Regulatory Sciences

Pediatric Labeling Best Practices

A large percentage of drugs are used off-label in pediatric patients. Unfortunately, when a patient uses a drug off-label, the drug is being used without FDA approval, which might result in...

Quality & Compliance

8 Common QMS Mistakes to Avoid

Previously in part two of this three-part blog series, “Mitigating Compliance Risk with Your Quality Management System,” we discussed how a robust and risk-based Quality Management System (QMS)...

Quality & Compliance

Mitigating Compliance Risk with Your Quality Management System

In the first blog of this three-part series, "Overlooking Your QMS Could Cost You," we discussed the cost of "good" versus "poor" quality, and the importance of investing in a "good" Quality...

Clinical Research Solutions

Enterprise Resource Planning (ERP) Systems in the Medical Industry

Drug and medical device development and manufacturing is a complex process that involves multiple supply chains, various monitoring systems, and countless players from R&D to market. Due to the...

Regulatory Sciences

Medical Device Regulation in the EU in the Midst of the COVID-19 Pandemic

Background: Medical Device Regulation in the EU Unlike device regulation in the U.S., which is governed by the FDA, in Europe, medical devices are not regulated by the EMA. Rather, medical device...

Quality & Compliance

Overlooking Your QMS Could Cost You

A Quality Management System (QMS) bridges an organization's individual compliance practices with regulatory requirements. It establishes the infrastructure and oversight requirements for...

Digital Transformation

Improve your R&D Strategy with These 6 Tips

In 2017, R&D investments in the pharmaceutical space reached more than $70 billion, with projected figures of over $200 billion by 2024. Pharma is one of the two sectors with semiconductors that are...

Regulatory Sciences

FDA Guidance for Non-COVID-19 Related Clinical Trials During the Pandemic

In March 2020, the FDA published a guidance entitled “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency - Guidance for Industry, Investigators, and Institutional...

Regulatory Sciences

FDA Works to Accelerate the Development of COVID-19 Treatments with New Guidance Documents

On Monday, May 11th, the FDA issued two guidance documents regarding the development of products indicated for the treatment and/or prevention of COVID-19. With these documents, the Agency intends to...

Pharmacovigilance

Clinical Trials in the Midst of COVID-19, Part One: European Medicines Agency (EMA)

Disclaimer As of April 23, 2020 Each health authority within the EU has information regarding COVID-19 (coronavirus) on its website. In this blog we will try to guide you through some of these...

Hands typing on laptop

Digital Transformation

Questions to Ask Before Implementing Data Standards in Science

In order to optimize the storage and reuse of data within your organization, we recommend that you consider implementing data standards throughout your business. In our previous blog post "An...

Quality & Compliance

EMA Extends Due Date for Nitrosamines Impurities Risk Assessment Due to COVID-19

EMA has extended the deadline to assess the risk of nitrosamine impurities to 31 March 2021. This decision was made based on the reports of the challenges encountered in meeting the original deadline...